Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The prognosis in case of non-small cell lung cancer (NSCLC) remains poor, and novel treatment modalities are urgently needed for advanced NSCLC. Backed by advances in the understanding of cancer biology, gene therapy has been developed in recent years. The p53 gene is altered in over 50% of cancers and has been extensively studied as a tumor suppressor gene. Adenoviral-mediated p53 gene transfer is currently under clinical evaluation worldwide for the treatment of cancer. We are now conducting a phase I study of Ad-p53 for advanced NSCLC patients in Japan. As an interim report, we provide a brief summary of the current status of this study, highlighting the safety and clinical efficacy of Ad-p53. As of September 2002, 13 patients were enrolled to this study, and safety and antitumor effects have been noted.

Original languageEnglish
Pages (from-to)193-197
Number of pages5
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume30
Issue number2
Publication statusPublished - Feb 2003

Fingerprint

p53 Genes
Non-Small Cell Lung Carcinoma
Genetic Therapy
Japan
Safety
Neoplasm Genes
Tumor Suppressor Genes
Neoplasms
Therapeutics
Clinical Studies

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Cite this

@article{7b1e402dcd0840f5a7c6205a0ca412d7,
title = "Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan",
abstract = "The prognosis in case of non-small cell lung cancer (NSCLC) remains poor, and novel treatment modalities are urgently needed for advanced NSCLC. Backed by advances in the understanding of cancer biology, gene therapy has been developed in recent years. The p53 gene is altered in over 50{\%} of cancers and has been extensively studied as a tumor suppressor gene. Adenoviral-mediated p53 gene transfer is currently under clinical evaluation worldwide for the treatment of cancer. We are now conducting a phase I study of Ad-p53 for advanced NSCLC patients in Japan. As an interim report, we provide a brief summary of the current status of this study, highlighting the safety and clinical efficacy of Ad-p53. As of September 2002, 13 patients were enrolled to this study, and safety and antitumor effects have been noted.",
author = "Shunsuke Kagawa and Toshiyoshi Fujiwara and Noriaki Tanaka",
year = "2003",
month = "2",
language = "English",
volume = "30",
pages = "193--197",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical study of adenoviral mediated p53 gene therapy for non-small cell lung cancer in Japan

AU - Kagawa, Shunsuke

AU - Fujiwara, Toshiyoshi

AU - Tanaka, Noriaki

PY - 2003/2

Y1 - 2003/2

N2 - The prognosis in case of non-small cell lung cancer (NSCLC) remains poor, and novel treatment modalities are urgently needed for advanced NSCLC. Backed by advances in the understanding of cancer biology, gene therapy has been developed in recent years. The p53 gene is altered in over 50% of cancers and has been extensively studied as a tumor suppressor gene. Adenoviral-mediated p53 gene transfer is currently under clinical evaluation worldwide for the treatment of cancer. We are now conducting a phase I study of Ad-p53 for advanced NSCLC patients in Japan. As an interim report, we provide a brief summary of the current status of this study, highlighting the safety and clinical efficacy of Ad-p53. As of September 2002, 13 patients were enrolled to this study, and safety and antitumor effects have been noted.

AB - The prognosis in case of non-small cell lung cancer (NSCLC) remains poor, and novel treatment modalities are urgently needed for advanced NSCLC. Backed by advances in the understanding of cancer biology, gene therapy has been developed in recent years. The p53 gene is altered in over 50% of cancers and has been extensively studied as a tumor suppressor gene. Adenoviral-mediated p53 gene transfer is currently under clinical evaluation worldwide for the treatment of cancer. We are now conducting a phase I study of Ad-p53 for advanced NSCLC patients in Japan. As an interim report, we provide a brief summary of the current status of this study, highlighting the safety and clinical efficacy of Ad-p53. As of September 2002, 13 patients were enrolled to this study, and safety and antitumor effects have been noted.

UR - http://www.scopus.com/inward/record.url?scp=0037315689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037315689&partnerID=8YFLogxK

M3 - Article

C2 - 12610865

AN - SCOPUS:0037315689

VL - 30

SP - 193

EP - 197

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 2

ER -